Adicet Bio Reports Inducement Grant under Nasdaq LR 5635(c)(4)
31 Dec 2024 //
BUSINESSWIRE
Adicet Doses 1st Patient in Ph 1 of ADI-270 for Renal Carcinoma
19 Dec 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
BUSINESSWIRE
Adicet Doses First Lupus Nephritis Patient in ADI-001 Ph 1 Trial
18 Nov 2024 //
BUSINESSWIRE
Adicet Bio Presents CAR T Cell Therapy Data at ACR 2024
16 Nov 2024 //
BUSINESSWIRE
Adicet Bio to Present at ACR Convergence 2024
05 Nov 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants Under Nasdaq Rule 5635
31 Oct 2024 //
BUSINESSWIRE
Adicet Bio Announces FDA Clearance For ADI-001 In Myopathy
16 Oct 2024 //
BUSINESSWIRE
Adicet Opens Enrollment For Ph 1 Trial In Autoimmune Diseases
30 Sep 2024 //
BUSINESSWIRE
Adicet Reports Q2 2024 Results And Provides Business Updates
13 Aug 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Jul 2024 //
BUSINESSWIRE
Adicet Bio`s ADI-270 Gets FDA Fast Track For Advanced Renal Cell Carcinoma
08 Jul 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28 Jun 2024 //
BUSINESSWIRE
Adicet Bio clears FDA IND application for ADI-270 in renal cell carcinoma.
24 Jun 2024 //
BUSINESSWIRE
Adicet Bio receives US FDA fast track design ADI-001 for classIV lupus nephritis
07 Jun 2024 //
PHARMABIZ
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
05 Jun 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 May 2024 //
BUSINESSWIRE
Adicet Presents ADI-270 Preclinical Data At EHA 2024 Congress
14 May 2024 //
BUSINESSWIRE
Adicet Reports Q1 2024 Results, Business Updates
14 May 2024 //
BUSINESSWIRE
Adicet Bio At Citizens JMP Life Sciences Conference
07 May 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30 Apr 2024 //
BUSINESSWIRE
Adicet`s ADI-270 IND Readiness Data At ASGCT
22 Apr 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
28 Mar 2024 //
BUSINESSWIRE
Adicet Reports4Q FYR 2023 & Highlights Recent Company Progress
19 Mar 2024 //
BUSINESSWIRE
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright Conference
11 Mar 2024 //
BUSINESSWIRE
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering
25 Jan 2024 //
BUSINESSWIRE
Adicet Bio, Inc. Announces Proposed Public Offering
22 Jan 2024 //
PRESS RELEASE
Adicet Bio, Inc. Announces Pricing of Public Offering
22 Jan 2024 //
BUSINESSWIRE
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
04 Jan 2024 //
BUSINESSWIRE
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline
03 Jan 2024 //
PRESS RELEASE
Adicet Bio Highlights ADI-001 Expansion
10 Dec 2023 //
BUSINESSWIRE
Adicet Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
07 Nov 2023 //
BUSINESSWIRE
Adicet to Present Posters Highlighting Allogeneic Gamma Delta T Cell Platform
27 Sep 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Aug 2023 //
BUSINESSWIRE
Adicet Reports Second Quarter 2023 Financial Results & Provides Business Updates
09 Aug 2023 //
BUSINESSWIRE
Adicet Announces Appointment of Katie Peng to the Board of Directors
11 Jul 2023 //
BUSINESSWIRE
Adicet Bio’s shares halved after PhI look at cell therapy
27 Jun 2023 //
ENDPTS
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial
26 Jun 2023 //
BUSINESSWIRE
Adicet Bio Reports Induction Grants under Nasdaq Listing Rule 5635(c)(4)
31 May 2023 //
BUSINESSWIRE
Adicet Reports1Q 2023 FYR and Provides Business Updates
09 May 2023 //
BUSINESSWIRE
Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference
09 May 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28 Apr 2023 //
BUSINESSWIRE
Adicet to Participate in 2023 Canaccord Genuity Horizons in Oncology Conference
13 Apr 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Mar 2023 //
BUSINESSWIRE
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
09 Mar 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28 Feb 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2023 //
BUSINESSWIRE
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial
10 Dec 2022 //
BUSINESSWIRE
Adicet Bio to Host Investor Webcast to Discuss Data from Ongoing ADI-001
02 Dec 2022 //
BUSINESSWIRE
Adicet Bio to Present at the Virtual JMP Securities Hematology Oncology Summit
30 Nov 2022 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
30 Nov 2022 //
BUSINESSWIRE
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President
29 Nov 2022 //
BUSINESSWIRE
Adicet Reports3Q 2022 Financial Results and Provides Business Updates
08 Nov 2022 //
BUSINESSWIRE
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs
07 Nov 2022 //
BUSINESSWIRE
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
01 Nov 2022 //
BUSINESSWIRE
Adicet Bio to Present at Upcoming Investor Conferences
07 Sep 2022 //
BUSINESSWIRE
Adicet Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
BUSINESS WIRE
Adicet Bio to Present at Upcoming Investor Conferences
21 Jun 2022 //
BUSINESSWIRE